References
- Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics 27(10), 861–872 (2009).
- DiMasi JA, Caglarcan E, Wood-Armany M. Emerging role of pharmacoeconomics in the research and development decision-making process. Pharmacoeconomics 19(7), 753–766 (2001).
- Nichol MB, Knight TK, Epstein J, Honda DH, Tretiak R. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers. J. Manag. Care Pharm. 13(4), 360–371 (2007).
- Olson BM, Armstrong EP, Grizzle AJ, Nichter MA. Industry's perception of presenting pharmacoeconomic models to managed care organizations. J. Manag. Care Pharm. 9(2), 159–167 (2003).
- The AMCP format for formulary submissions version 3.0. J. Manag. Care Pharm. 16(1 Suppl. A), 1–30 (2010).
- Neumann PJ, Sullivan SD, Schur C, Gupta J, Berk M. PHP24 use of the amcp format in the u.s.:a national survey of health plans. Value Health 11(6), A369 (2008).
- Neumann PJ, Lin PJ, Hughes TE. US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness research. Pharmacoeconomics 29(8), 687–692 (2011).
- Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. N. Engl. J. Med. 363(16), 1495–1497 (2010).
- Spooner JJ, Gandhi PK, Connelly SB. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan. J. Manag. Care Pharm. 13(1), 37–43 (2007).